TaiMed Biologics Inc. is a biotechnology company with focuses on the prevention and treatment of viral infectious diseases. The Company collaborates with other companies and government to conduct trials of AIDs treatment.

The Company’S Board Of Directors Resolved To
Issue Employee Stock Warrants

Taimed Biologics Announces The Completion Of Last
Participant Last Visit In Phase 2a Study Of Long-Acting
Tmb-365 And Tmb-380 Combination Therapy For Hiv

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Taimed Biologics (4147 TT)

The Company’S Board Of Directors Resolved To Issue Employee Stock Warrants

Taimed Biologics Announces The Completion Of Last Participant Last Visit In Phase 2a Study Of Long-Acting Tmb-365 And Tmb-380 Combination Therapy For Hiv

The Company'S 2024 Q3 Consolidated Financial Statements Have Been Approved By The Board Of Directors

Announcement Of The Company'S Board Meeting Date Of The Third Quarter 2024 Consolidated Financial Report

Taimed Has Secured Its First Cdmo Contract From An International Client

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)